DATA FROM DAISY PETAL STUDY WILL BE PRESENTED IN THREE SESSIONS
SAN DIEGO, June 16, 2011 /PRNewswire via COMTEX/ --
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that three elagolix presentations have been accepted for the scientific program at 2011 World Congress on Endometriosis, to be held September 4-7, 2011 in Montpellier, France. This important meeting is sponsored by the World Endometriosis Society and occurs every three years, bringing together clinicians and basic scientists from all over the world to share the latest developments in endometriosis.
"We are very pleased to participate in this prestigious scientific event," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine. "This Congress will highlight the marked increase in both the basic science and clinical research related to endometriosis that has occurred in recent years. Endometriosis profoundly impacts the lives of well over one hundred million women worldwide, and global efforts to improve our understanding of the disorder, its symptoms and treatment, are the highlights of this triennial meeting. We are excited to be an integral part of these initiatives and to provide a detailed update on our potential new therapy."
The acceptance of multiple abstracts and datasets from the development program of elagolix for endometriosis at the 2011 World Congress on Endometriosis is as follows:
Data from the recently completed Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will be presented in a speaking session:
- "Elagolix, A Novel Oral GnRH Antagonist, Significantly Reduced Endometriosis-Associated Pelvic Pain: Results For The Placebo-Controlled, Double-Blind Period Of A Randomized Phase 2 Study" on Wednesday, September 7, 2011 at 10:30 am
Data from the recently completed Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will also be presented in two distinct poster sessions:
- "Elagolix, A Novel Oral GnRH Antagonist Improves Quality Of Life In Women With Endometriosis-Associated Pelvic Pain" on Tuesday, September 6, 2011 at 8:00 am
- "Elagolix, A Novel Oral GnRH Antagonist, Maintained Reduction Of Endometriosis-Associated Pelvic Pain During 24 Weeks Of Treatment" on Wednesday, September 7, 2011 at 8:00 am
In addition, data from the extensive work undertaken to improve our understanding of endometriosis symptoms will be presented at the 11th World Congress on Endometriosis in two separate sessions:
- "A Qualitative Evaluation of Disease Severity and Bothersomeness of Symptoms In Patients with Endometriosis" on Tuesday, September 6, 2011 at 8:00 am
- "Perception of Pelvic Pain in Women with Endometriosis: A Focus Group Study" on Wednesday, September 7, 2011 at 11:30 am.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com
In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and report on Form 10-Q for the quarter ended March 31, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.
SOURCE Neurocrine Biosciences, Inc.